RadNet, Inc. has recently made a significant strategic move by acquiring Gleamer SAS for a sum of up to €230 million. This acquisition is poised to elevate RadNet's subsidiary, DeepHealth, to the forefront of the global radiology artificial intelligence market. The all-cash transaction integrates Gleamer's cutting-edge X-ray and musculoskeletal AI technologies, which have received FDA clearance, directly into DeepHealth's comprehensive suite of solutions. This integration is anticipated to usher in substantial improvements in diagnostic accuracy and operational efficiency within the healthcare sector.
On March 2, 2026, the agreement was finalized, marking a pivotal moment for both entities. Gleamer, a Paris-based company, brings to the table a robust portfolio, serving approximately 700 clients worldwide. The company has demonstrated impressive growth, with its Annual Recurring Revenue (ARR) expanding by 90% between 2022 and 2025, and projections indicating an ARR of $30 million by 2026. This acquisition is a testament to RadNet's commitment to advancing healthcare through innovative AI solutions. The integration of Gleamer's technology is expected to be fully realized by the third quarter of 2026, promising a future where medical diagnostics are more precise and streamlined.
Following the acquisition, DeepHealth showcased its newly expanded, industry-leading clinical AI portfolio at ECR 2026 on March 4, 2026. This updated platform now seamlessly incorporates Gleamer's AI capabilities across various imaging modalities, including MR, CT, X-ray, Ultrasound, and Mammography. The result is a series of specialized clinical AI suites designed for critical areas such as breast, chest, neuro, and prostate care. These modular suites are specifically engineered to enable earlier detection of diseases and automate reporting processes, thereby facilitating a transformative shift in disease management.
RadNet, established in 1981 and headquartered in California, has long been recognized as the largest operator of outpatient diagnostic imaging centers in the United States. Its continued investment in advanced technologies like AI underscores its dedication to maintaining a leadership position in the diagnostic imaging industry and its mission to enhance patient outcomes through state-of-the-art medical solutions.
The acquisition of Gleamer by RadNet marks a transformative step in the field of diagnostic imaging, significantly bolstering DeepHealth's standing as a premier AI solution provider. This strategic integration of advanced AI technologies is set to revolutionize disease detection and reporting, ultimately enhancing healthcare efficiency and patient care.